Expansion Opportunities Target partnerships and collaborations to expand Erasca’s pipeline by engaging academic labs and biopharma companies that have disclosed potential new cancer mechanisms, aligning with their open approach to multiple therapeutic modalities.

Clinical Momentum Leverage positive Phase 1 data while addressing ongoing legal and regulatory risks to position discussions with investors and partners around validated early signals, while offering risk-mitigated co-development or in-licensing options.

IP & Risk Monitor and address patent infringement and trade secret concerns related to ERAS-0015 to reassure potential collaborators and provide joint IP risk assessment services, potentially offering due diligence and defensive collaboration structures.

Financial Health Capitalize on current funding and sizable revenue to pursue strategic partnerships, co-development deals, and milestone-driven programs with mid-to-large biotech players seeking growth opportunities in oncology pipelines.

Technology Enablement Position Erasca as a partner for data-driven drug discovery and target validation by offering access to their open platform approach and collaboration with their ecosystem, appealing to organizations seeking diverse mechanisms for precision oncology.